JPWO2003022231A1 - Hair growth and hair growth compositions - Google Patents

Hair growth and hair growth compositions Download PDF

Info

Publication number
JPWO2003022231A1
JPWO2003022231A1 JP2003526361A JP2003526361A JPWO2003022231A1 JP WO2003022231 A1 JPWO2003022231 A1 JP WO2003022231A1 JP 2003526361 A JP2003526361 A JP 2003526361A JP 2003526361 A JP2003526361 A JP 2003526361A JP WO2003022231 A1 JPWO2003022231 A1 JP WO2003022231A1
Authority
JP
Japan
Prior art keywords
alopecia
hair
hair growth
ehretia
substituent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003526361A
Other languages
Japanese (ja)
Inventor
秀 道広
道広 秀
大谷 和弘
和弘 大谷
小池 透
透 小池
直明 森原
直明 森原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakunaga Pharmaceutical Co Ltd
Original Assignee
Wakunaga Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakunaga Pharmaceutical Co Ltd filed Critical Wakunaga Pharmaceutical Co Ltd
Publication of JPWO2003022231A1 publication Critical patent/JPWO2003022231A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/30Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Abstract

本発明は天然物またはその抽出物等を有効成分とする副作用の少ない発毛用または育毛用組成物の提供をその目的とする。本発明による発毛用または育毛用組成物は、ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物を有効成分として含んでなるものである。An object of the present invention is to provide a hair-growing or hair-restoring composition having a natural product or an extract thereof as an active ingredient and having few side effects. The composition for hair growth or hair growth according to the present invention comprises a plant of the genus Boraginaceae and the genus Ehretia as an active ingredient.

Description

発明の背景
発明の分野
本発明は、優れた発毛および育毛効果を有するムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物を有効成分とする発毛用および育毛用組成物に関し、更には優れた発毛および育毛効果を有するフクマンギ(Ehretia microphyllaCarmona retusa)を有効成分とする発毛用および育毛用組成物に関する。本発明はまた、ミクロフィロン(Microphyllone)誘導体を有効成分として含有してなる発毛用および育毛用組成物に関する。
関連技術
従来から発毛剤および育毛剤については盛んに研究が行われ、養毛化粧品、医薬品および医薬部外品として多くの製品が開発されている。これらの製品には、育毛成分として血行促進・血流改善を目的としたセンブリエキス、トウガラシチンキ、ビタミンE誘導体、霊芝エキス、アセチルコリン誘導体およびニコチン酸誘導体、抗男性ホルモンとしてエストラジオールなどの女性ホルモン剤、細胞の活性化を目的としたジアルキルモノアミン誘導体、ペンタデカン酸グリセリド、亜鉛などのミネラル、免疫抑制剤、代謝促進剤等が配合され、発毛や育毛に用いられてきた。
しかしながら、その効果は十分なものとはいえず、より優れた発毛剤および育毛剤が望まれている。また、5α−リダクターゼ阻害剤などの合成医薬品も発毛剤および育毛剤として知られているが、副作用の問題などが懸念されることから、天然物またはその抽出物等を有効成分とする副作用の少ない発毛剤および育毛剤が望まれている。
特開平10−36229号公報にはステビア属(Stevia Cav.)に属する植物の抽出物を有効成分とする育毛剤が、また、特開2002−37715号公報にはプロシアニジンまたはプロシアニジンを含む植物抽出エキスを有効成分とする育毛剤が開示されている。しかしながら、いずれの育毛剤も育毛効果の点で改善の余地を残すものであった。
発明の概要
本発明者等は今般、ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物、特に、フクマンギ(Ehretia microphyllaCarmona retusa)およびミクロフィロン誘導体が優れた発毛および育毛効果を有することを見出した。本発明はこの知見に基づくものである。
フクマンギは、ムラサキ科チシャノキ属植物であり、フィリピンでは野生のお茶を意味するTsaang−gubatとして知られ、非炎症性の病気に用いられている。葉から調製したお茶は健胃剤として、また葉の煎じ汁は咳、出血を伴う下痢、赤痢に用いられている。Tsaang−gubatの錠剤はフィリピンの食品医薬品局に登録されており、腹痛の緩和、腸の蠕動運動の抑制が確認されている。また、南インドでは、その根を悪液質や梅毒の治療に用いている。しかしながら、ムラサキ科チシャノキ属植物、特に、フクマンギが発毛および育毛効果を有することは知られていない。
本発明は副作用の少ない発毛用または育毛用組成物の提供をその目的とする。
本発明による発毛用または育毛用組成物は、ムラサキ科チシャノキ属植物を有効成分として含んでなるもの、である。
本発明による発毛用または育毛用組成物はまた、ミクロフィロン誘導体を有効成分として含んでなるもの、である。
ムラサキ科チシャノキ属植物、特に、フクマンギおよびミクロフィロン誘導体は優れた発毛および育毛効果を有する。従って、本発明による組成物を発毛剤、育毛剤または健康食品として使用することで、発毛および育毛効果並びに脱毛の治療および予防効果が期待できる。
発明の具体的説明
本発明において「発毛」および「育毛」とは、頭毛の発毛および育毛のみならず、頭毛以外の体毛の発毛および育毛や、頭毛および頭毛以外の体毛の脱落の防止も含む。本発明において「育毛」は「養毛」を含む意味で用いられるものとする。
本発明において有効成分として用いることができるムラサキ科チシャノキ属植物としては、フクマンギ(Ehretia microphyllaCarmona retusa)、リュウキュウチシャノキ(Ehretia dich otoma)、チシャノキ(Ehretia ovalifolia)、ヒロハチシャノキ(Ehretia ovalifolia var. latifolia)、マルバチシャノキ(Ehretia dicksonii)、Ehretia acuminataEhretia amoenaEhretia anacuaEhretia asperaEhretia buxifoliaEhretia cymosaEhretia grahamiiEhretia laevisEhretia philippinensisEhretia wallichianaが挙げられる。本発明においてはこれらの植物を単独であるいは組み合わせて有効成分として用いることができる。
本発明において使用される植物は、そのいずれの部分を有効成分として用いてもよいが、例えば、葉や茎を用いることができる。本発明において使用される植物は、乾燥物、乾燥粉末、および抽出物等の形態をとることができるが、特に抽出物が好ましい。
本発明において「抽出物」とは、植物を溶媒で抽出して得られる抽出液、その希釈液、濃縮液、およびエキス、並びにこれらを凍結乾燥法等により乾燥して得られる乾燥物を意味する。
植物の抽出物は公知の方法に従って製造できる。すなわち、植物体、例えば、葉、葉の乾燥物、茎、または茎の乾燥物を、粉砕、破砕、裁断したものに極性または非極性溶媒を加え、適当な溶媒によって抽出を行なった後、必要に応じて濾過・遠心分離等の操作により不溶物を除き、濃縮することにより抽出物を得ることができる。また、必要に応じて、水で洗浄し、酢酸エチル、ジエチルエーテル、ヘキサンなどの非極性溶媒で抽出することにより精製してもよい。
抽出に用いる「溶媒」としては、水;メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール等のアルコール類;1,4−ジオキサン等のエーテル類;アセトン等のケトン類;アセトニトリル等のニトリル類のような極性溶媒が挙げられる。抽出に用いる「溶媒」としてはまた、ベンゼン、トルエン、キシレンなどのような芳香族炭化水素類;テトラヒドロフラン、ジオキサン、モノグライムなどのようなエーテル類;塩化メチレン、クロロホルム、四塩化炭素などのようなハロゲン化炭化水素類;酢酸エチル;あるいはこれらの混合液が挙げられる。好ましい溶媒としては、水;メタノール、エタノール等の低級アルコール;およびこれらの混合液である。
植物の乾燥粉末は公知の方法に従って製造できる。例えば、植物体を乾燥させて乾燥物を得、次いで乾燥物を裁断および/または粉砕処理することにより乾燥粉末を得ることができる。植物の乾燥方法としては、例えば、加熱乾燥、減圧乾燥、風乾などの方法が挙げられる。植物の裁断および粉砕方法としては、例えば、乾燥処理した植物体(例えば、葉や茎)を小片または小塊に切断または破砕した後、あるいは粗切り、中切り、または細切りした後、粉砕器等を用いて粗末、中末、細末、または微末に粉砕する方法が挙げられる。
ミクロフィロン誘導体は、フクマンギの抽出物を適当な公知の分離手段、例えばシリカゲルクロマト法、高速液体クロマト法等に適用することにより単離することができる。
ミクロフィロン誘導体は下記式(I)で表すことができる。

Figure 2003022231
(上記式中、Rは水素原子またはアルキル基を示し、Rは水素原子、置換基を有していてもよいビニル基または置換基を有していてもよいアリル基(−CH−CH=CH)を示し、Rは水素原子を表し、RとRは一緒になって結合または置換基を有していてもよい炭素数1〜5のアルキレン鎖を形成してもよく、Aは酸素原子、硫黄原子または単結合を示し、−−−は単結合または二重結合を表す)
式(I)中、Rが表すことがあるアルキル基としては、炭素数1〜8の直鎖または分岐鎖のアルキル基が挙げられ、炭素数1〜5の直鎖または分岐鎖のアルキル基が好ましく、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル、tert−ブチル、n−ペンチルが特に好ましい。
が表すことがあるビニル基の置換基としては、ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルキル基(例えば、−C(−CH(−CHOH));ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数2〜5のアルケニル基(例えば、−C(−CH)(=CH));ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルコキシ基;ヒドロキシ基;カルボキシル基;アミノ基等が挙げられる。
が表すことがあるアリル基の置換基としては、ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルキル基(例えば、1または2のメチル基);ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数2〜5のアルケニル基;ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルコキシ基;ヒドロキシ基;カルボキシル基;アミノ基等が挙げられる。
とRは一緒になって結合または炭素数1〜5、好ましくは炭素数1〜3、のアルキレン鎖を形成していてもよい。この場合形成されうる環としては、炭素数3〜8のシクロアルカン、好ましくは炭素数3〜6のシクロアルカン(例えば、シクロプロパン、シクロブタン、シクロペンタン)が挙げられる。このアルキレン鎖は場合によっては置換基を有していてもよく、このような置換基としては、ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルキル基;ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数2〜5のアルケニル基(例えば、−C(−CH)(=CH));ヒドロキシ基、炭素数1〜5のアルコキシ基等の置換基を有していてもよい炭素数1〜5のアルコキシ基;ヒドロキシ基;カルボキシル基;アミノ基等が挙げられる。
式(I)の好ましい化合物としては、Rが炭素数1〜8のアルキル基を表し、Rが置換基を有していてもよいビニル基または置換基を有していてもよいアリル基を表し、Rが水素原子を表し、Aが単結合を表し、−−−が二重結合を表す化合物が挙げられ、より好ましくはRが炭素数1〜5のアルキル基を表し、Rが置換基を有していてもよいアリル基を表し、Rが水素原子を表し、Aが単結合を表し、−−−が二重結合を表す化合物であり、特に好ましくは、Rがメチルを表し、Rが2つのメチルにより置換されたアリル(−CH−CH=C(−CH)を表し、Rが水素原子を表し、Aが単結合を表し、−−−が二重結合を表す化合物である。
式(I)の化合物にはシス体およびトランス体等の幾何異性体、d体−、l体−等の光学異性体、および回転異性体等の各種異性体が存在し得るが、本発明はそれら何れの異性体も包含するものである。
本発明による組成物には、必要に応じてニンジンエキス、センブリエキス、ニンニクエキス、アロエエキス、トウガラシエキス等の植物抽出エキス;ビタミンB6、ビタミンEおよびその誘導体、ビオチン等のビタミン類;グリチルリチン酸、グリチルレチン酸、塩酸ジフェンヒドラミン等の消炎剤;ヒノキチオール、フェノキシエタノール、サリチル酸等の殺菌剤;エストラジオール等の抗男性ホルモン剤;亜鉛等のミネラル;ミノキシジル等の合成医薬品等を更に配合することができる。また、本発明の効果を損なわない範囲で、界面活性剤、酸化防止剤、香料、ゲル化剤、着色剤、防腐剤、角質溶解剤、pH調整剤、アルコール類および水などを本発明による組成物に適宜配合することができる。
本発明による組成物は、発毛や育毛を目的とする医薬、医薬部外品、化粧品または飲食料等の食品として用いることができる。投与形態は特に限定されないが、外皮投与、経口投与および注射による投与等の一般的投与経路を挙げることができる。
外皮投与のための製剤としては、軟膏、クリーム、ゲル、乳液、液状、ローション状、シャンプー、リンス、トニック、エアゾールなどの外皮に適用できる種々の剤型が挙げられ、経口投与のための固形剤としては、カプセル剤、錠剤、丸剤、トローチ剤、散剤および顆粒剤等が挙げられ、経口投与のための液体製剤としては、当時業者間で普通に使用される不活性希釈剤、例えば水を含む製薬上許容し得る乳剤、溶液、懸濁剤、シロップ剤およびエリキシル剤が挙げられる。これらの各種製剤は通常用いられている賦形剤、補助剤、および添加剤のような製剤用添加物を用いて常法により製造することができる。
食品として用いる場合の形態としては、固形食品、クリーム状、あるいはジャム状の半流動食品や、ゲル状食品、飲料等のあらゆる食品形態にすることが可能であり、例えば、粉末、カプセル、顆粒、タブレット、ドリンク剤等の形態が挙げられる。これらの各種食品は通常用いられている食品添加物を用いて製造してもよい。
ムラサキ科チシャノキ属植物(例えば、フクマンギ)の投与量は、投与経路、所望の処置期間およびその他の要因に依存して決定できるが、一般に一日当り約5〜1500mg/kg、特に約30〜600mg/kgが好ましい。また、所望によりこの一日量を2〜4回に分割して投与してもよい。
フクマンギの抽出物の有効投与量は、投与経路、所望の処置期間およびその他の要因に依存して決定できるが、一般に一日当り約5〜750mg/kg、特に約50〜400mg/kgが好ましい。また、所望によりこの一日量を2〜4回に分割して投与してもよい。
ミクロフィロン誘導体の有効投与量は、投与経路、所望の処置期間およびその他の要因に依存して決定できるが、一般に一日当り約0.1〜250mg/kg、特に約1〜100mg/kgが好ましい。また、所望によりこの一日量を2〜4回に分割して投与することもできる。
本発明による発毛用および育毛用組成物を、男性型脱毛症、脂漏性脱毛症、老人性脱毛症、円形脱毛症、粃糠性脱毛症、結髪性脱毛症、薬物性脱毛症、放射線脱毛症およびストレス性脱毛症のような脱毛症に適用することにより、発毛および育毛が促進され、脱毛を改善することができる。すなわち本発明による組成物はこれらの疾患の治療および予防に用いることができる。
さらに本発明による発毛用および育毛用組成物は、フケ、カユミ、薄毛、抜け毛などの改善或いは予防効果を有する。
本発明による発毛用および育毛用組成物はヒト以外の動物、例えば、サル、イヌ、ネコ、ウサギ、モルモットなどの哺乳類、オウム、インコ、カナリアなどの鳥類等に使用できる。これらの動物はペットとして飼育され、ストレスあるいは病気等による脱毛や抜け毛などの症状が多く見られるようになってきている。従って、本発明による発毛用および育毛用組成物はこれらの動物に対しても有効である。
本発明によれば、発毛剤または育毛剤の製造のための、ムラサキ科チシャノキ属植物の使用が提供される。
本発明によればまた、発毛剤または育毛剤の製造のための、ミクロフィロン誘導体の使用が提供される。
本発明によれば、ムラサキ科チシャノキ属植物の治療上または予防上の有効量を必要であれば薬学上許容される担体とともに哺乳類に投与する工程を含んでなる、発毛または育毛方法が提供される。
本発明によればまた、ミクロフィロン誘導体の治療上または予防上の有効量を必要であれば薬学上許容される担体とともに哺乳類に投与する工程を含んでなる、発毛または育毛方法が提供される。
本発明の好ましい態様によれば、フクマンギの抽出物を有効成分として含んでなる、発毛用または育毛用組成物が提供される。
本発明の好ましい態様によれば、発毛剤または育毛剤の製造のための、フクマンギの抽出物の使用が提供される。
本発明の好ましい態様によれば、フクマンギの抽出物の治療上または予防上の有効量を必要であれば薬学上許容される担体とともに哺乳類に投与する工程を含んでなる、発毛または育毛方法が提供される。
実 施 例
以下、実施例を挙げて本発明を詳細に説明するが、本発明はこれらに限定されるものではない。
実施例1:フクマンギメタノール抽出エキスおよびミクロフィロン原末の調製(1)
フクマンギ葉4kgをメタノール3リットルで、加温抽出を行なった。ろ過した後、残渣にメタノール3リットルを加え、同様に抽出した。この抽出操作を合計4回行なった。ろ液を合わせ溶媒を留去し、メタノールエキスを450g得た。このメタノールエキスを70%(v/v)メタノールに溶解し、エーテルにて抽出し、溶媒を留去しエーテルエキスを200g得た。このエーテルエキスをシリカゲルカラムクロマトグラフィー(溶媒、ヘキサン:エタノール=5:1)にて分画し、ミクロフィロン含有画分を10g得た。この画分をさらにRP−18カラムクロマトグラフィー(溶媒、65%メタノール)にて分画して得た粗ミクロフィロンをエタノールにて再結晶し、ミクロフィロン原末を150mg得た。
実施例2:フクマンギエタノール柚出エキスおよびミクロフィロン原末の調製(2)
フクマンギ茎1kgをエタノール3リットルで、加温抽出を行なった。ろ過した後、残渣にエタノール3リットルを加え、同様に抽出した。この抽出操作を合計4回行なった。ろ液を合わせ溶媒を留去し、エタノールエキスを80g得た。このエタノールエキスをシリカゲルカラムクロマトグラフィー(溶媒、ヘキサン:エタノール=5:1)にて分画し、ミクロフィロン含有画分を8g得た。この画分をさらにRP−18カラムクロマトグラフィー(溶媒、65%メタノール)にて分画して得た粗ミクロフィロンをエタノールにて再結晶し、ミクロフィロン原末を500mg得た。
実施例3:ミクロフィロン軟膏の調製
ミクロフィロン原末(実施例1)2.5mgを陶器製の軟膏練り皿上に載せ、流動パラフィンを1滴たらした後ガラス棒を用いて混合、溶解した。へらで混合しながら軟膏基材のプラスチベース0.25gを少しずつ加え、練合し、1%ミクロフィロン軟膏を調製した。調製したミクロフィロン軟膏は、冷所で保存した。
実施例4:フクマンギエキス軟膏の調製
フクマンギエタノール抽出エキス(実施例2)10mgを陶器製の軟膏練り皿上に載せ、流動パラフィンを数滴たらした後ガラス棒を用いて混合、溶解した。へらで混合しながら軟膏基材のプラスチベース0.2gを少しずつ加え、練合し、5%フクマンギエキス軟膏を調製した。調製した5%フクマンギエキス軟膏は、冷所で保存した。
実施例5:1%ミクロフィロン軟膏の発毛および育毛効果試験(躯幹剃毛部への塗布による発毛および育毛効果)
BDF1マウスの腹部から背部に至る躯幹の体毛をバリカンで剃毛した後、1%ミクロフィロン軟膏(実施例3)約200mgを剃毛部分に薄く塗布した(塗布面積 約25cm)。7日後、再度約200mgのミクロフィロン軟膏を塗布し、実験開始16日および24日後に発毛および育毛状況を観察した。対照群として、ミクロフィロンを含まないプラスチベース軟膏を同様に塗布し、発毛および育毛状況を観察した。観察結果を、図1aおよび図1bに示す。1%ミクロフィロン軟膏塗布群では、腹部から背部に至る躯幹の剃毛部位の発毛および育毛は活発で、プラスチベース対照群に比べて著しい発毛および育毛効果が観察された。
実施例6:頬髯に対する発毛および育毛効果
腹部から背部に至る躯幹の体毛をバリカンで剃毛したBDF1マウスの頬髯をはさみで切り落とした後、1%ミクロフィロン軟膏(実施例3)約200mgを剃毛部分に薄く塗布した(塗布面積約25cm)。7日後、再度約200mgのミクロフィロン軟膏を塗布し、実験開始24日後の頬髯の伸長程度を観察した。対照群として、ミクロフィロンを含まないプラスチベース軟膏を同様に塗布したBDF1マウスを用いた。図2に示すように、ミクロフィロン軟膏塗布群では、対象群に比べて顕著な頬髯の伸長が観察された。この結果は、ミクロフィロンが経皮吸収され、直接塗布した部分以外にも発毛および育毛効果を発現することを示している。
実施例7:耳介部への塗布による頬髯発毛および育毛効果
Balb/cマウスの頬髯をはさみで切り落とした後、1%ミクロフィロン軟膏(実施例3)約40mgを左右耳介の裏表に塗布し、実験開始15日後の頬髯発毛および育毛状況を観察した。対照群としては、ミクロフィロンを含まないプラスチベース軟膏を用いた。ミクロフィロン軟膏を耳介に塗布した場合、図3に示すように対象群に比較して顕著な頬髯の伸張が観察された。同時に、躯幹の体毛の発毛および育毛効果も観察され、実施例6に示した結果と総合すると、ミクロフィロンが経皮吸収されてその発毛および育毛効果を発現すること、体毛のみならず頬髯に対しても発毛および育毛効果を有することを示している。
実施例8:5%フクマンギエタノールエキス軟膏の発毛および育毛効果試験(躯幹剃毛部への塗布による発毛および育毛効果)
BDF1マウスの腹部から背部に至る躯幹の体毛をバリカンで剃毛した後、5%フクマンギエキス軟膏(実施例4)約200mgを剃毛部分に薄く塗布した(塗布面積約25cm)。7日後、約200mgのミクロフィロン軟膏を塗布し、2週間後に発毛および育毛状況を観察した。対照群として、フクマンギエキスを含まないプラスチベース軟膏を同様に塗布し、発毛および育毛状況を観察した。観察結果を図4に示す。5%フクマンギエキス軟膏塗布群では、プラスチベース対照群に比べて腹部から背部に至る躯幹の剃毛部位の発毛および育毛は活発で、顕著な発毛および育毛作用が観察された。更に、頬髯の伸長も、フクマンギエキス塗布群で対照群に比較して有意に促進した(図5)。
実施例9:ミクロフィロンの静脈投与による発毛および育毛効果
BDF1マウスの腹部から背部に至る躯幹の体毛をバリカンで剃毛した後、生理食塩水に溶解したミクロフィロン原末(実施例1)を2mg/kgおよび6mg/kgの用量で尾静脈より投与した。対照として、生理食塩水を同様に静脈投与した。投与2週間後の発毛および育毛状態を観察したところ、何れの投与量においても躯幹部に塗布した場合と同様にミクロフィロン投与群で有意な発毛および育毛効果が観察され、その発毛および育毛効果は用量依存的であった。従って、ミクロフィロンおよびフクマンギエキスは、外用のみならず、静脈投与、経口投与等の投与によってもその発毛および育毛効果を有する。
実施例10:ミクロフィロンローションの調製
ミクロフィロン原末(実施例1)120mgを容器に取り、エタノール3.2ml、プロピレングリコール0.8mlを加え、溶解した。ミクロフィロンローションは、用時調製した。
実施例11:フクマンギエキスローションの調製
フクマンギエタノール抽出エキス(実施例2)200mgを容器に取り、エタノール3.2ml、プロピレングリコール0.8mlを加え、溶解させるために超音波処理を行った。フクマンギエタノール抽出エキスローションは、用時調製した。
実施例12:3%ミクロフィロンローションの発毛効果試験(躯幹剃毛部(背部)への塗布による発毛効果)
C3Hマウスの背部体毛をバリカンで剃毛した後、その翌日から3%ミクロフィロンローション(実施例10)200μlを剃毛部分に1日1回連日塗布した(塗布面積約20cm)。実験開始31日後に発毛状況を調べるために、剃毛部分の皮膚を剥離し、発毛部分の面積率を以下の式にて算出した。対照群として、ミクロフィロンを含まないローションを同様に塗布し、実験開始31日後における発毛部分の再生面積率を同様に算出した。毛の再生面積率の結果を、表1に示す。3%ミクロフィロンローション塗布群では、背部剃毛部位の発毛は活発で、ローション対照群に比べて有意な発毛効果が観察された。
Figure 2003022231
実施例13:5%フクマンギエタノールエキスローションの育毛効果試験(躯幹剃毛部(背部)への塗布による育毛効果
C3Hマウスの背部体毛を剃刀で剃毛した後、その翌日から5%フクマンギエキスローション(実施例11)200μlを剃毛部分に1日1回連日塗布した(塗布面積約20cm)。実験開始15日後に育毛状況を調べるために、剃毛部分の皮膚を剥離し、育毛部分の面積率を以下の式にて算出した。対照群として、フクマンギエキスを含まないローションを同様に塗布し、実験開始15日後における育毛部分の再生面積率を同様に算出した。毛の再生面積率の結果を、表2に示す。5%フクマンギエキスローション塗布群では、背部剃毛部位の発毛は活発で、ローション対照群に比べて有意な育毛効果が観察された。
Figure 2003022231

【図面の簡単な説明】
図1は、ミクロフィロンを含まないプラスチベース軟膏(Vehicle)および1%ミクロフィロン軟膏(1% microphyllon)をBDF1マウスの躯幹剃毛部へ塗布した場合の発毛および育毛効果を表す生物の形態の写真である。aは16日目、bは24日目の結果である。
図2は、ミクロフィロンを含まないプラスチベース軟膏(Vehicle)および1%ミクロフィロン軟膏(Microphyllon)をBDF1マウスの躯幹剃毛部へ塗布した場合の頬髯の伸長促進効果表す生物の形態の写真である。
図3は、ミクロフィロンを含まないプラスチベース軟膏(Vehicle(ear))および1%ミクロフィロン軟膏(MP(ear))をBalb/cマウスの耳介部へ塗布した場合の頬髯の伸長促進効果を表す生物の形態の写真である。
図4は、フクマンギエキスを含まないプラスチベース軟膏(対照群)および5%フクマンギエキス軟膏(フクマンギ群)をBDF1マウスの躯幹剃毛部へ塗布した場合の発毛および育毛効果を表す生物の形態の写真である。
図5は、フクマンギエキスを含まないプラスチベース軟膏(対照群)および5%フクマンギエキス軟膏(フクマンギ群)をBDF1マウスの躯幹剃毛部へ塗布した場合の頬髯の伸長促進効果を表す生物の形態の写真である。Background of the Invention
Field of the invention
The present invention relates to a purple family having excellent hair growth and hair growth effects (Boraginaceae)EhreiaThe present invention relates to a composition for hair growth and hair growth comprising a plant as an active ingredient, and more particularly to a fukumangi having excellent hair growth and hair growth effects.Ehreia  microphylla,Carmona  retusa) As an active ingredient. The present invention also relates to a hair-growing and hair-restoring composition comprising a microphyllone derivative as an active ingredient.
Related technology
BACKGROUND ART Hitherto, studies on hair growth agents and hair growth agents have been actively conducted, and many products have been developed as hair growth cosmetics, pharmaceuticals, and quasi-drugs. These products include assembly extracts, pepper tincture, vitamin E derivatives, ganoderma extract, acetylcholine derivatives and nicotinic acid derivatives as hair growth ingredients for promoting blood circulation and improving blood flow, and female hormones such as estradiol as antiandrogens. In addition, a dialkyl monoamine derivative for the purpose of activating cells, pentadecanoic acid glyceride, minerals such as zinc, an immunosuppressant, a metabolic promoter and the like have been blended and used for hair growth and hair growth.
However, the effect is not sufficient, and more excellent hair growth agents and hair growth agents are desired. Synthetic drugs such as 5α-reductase inhibitors are also known as hair growth agents and hair restorers. However, there are concerns about side effects and the like. Less hair growth and growth agents are desired.
JP-A-10-36229 discloses a stevia genus (Stevia  Cav.)), And Japanese Patent Application Laid-Open No. 2002-37715 discloses a hair restorer containing procyanidin or a plant extract containing procyanidin as an active ingredient. However, any hair restorer leaves room for improvement in terms of the hair restorer effect.
Summary of the Invention
The present inventors have recently reported thatBoraginaceae)Ehreia) Plants, especially fukumangi (Ehreia  microphylla,Carmona  retusa) And microfilon derivatives have excellent hair growth and hair growth effects. The present invention is based on this finding.
Fukumangi is a plant belonging to the genus Alaska in the Philippines, and is known in the Philippines as Tsaang-gubat, meaning wild tea, and is used for non-inflammatory diseases. Tea prepared from leaves is used as a stomachic, and leaf decoction is used for cough, diarrhea with bleeding, and dysentery. Tsaang-gubat tablets are registered with the Food and Drug Administration in the Philippines and have been confirmed to reduce abdominal pain and suppress intestinal peristalsis. In South India, its roots are used to treat cachexia and syphilis. However, it is not known that the plants belonging to the genus Tisanoki, especially Fukumangi, have hair growth and hair growth effects.
An object of the present invention is to provide a composition for hair growth or hair growth with few side effects.
The composition for hair growth or hair growth according to the present invention comprises a plant belonging to the genus Tisanoki as the active ingredient.
The composition for hair growth or hair growth according to the present invention also comprises a microfilon derivative as an active ingredient.
The purple genus plants, especially the fukumangi and microphylon derivatives, have excellent hair growth and hair growth effects. Therefore, by using the composition according to the present invention as a hair growth agent, a hair restorer or a health food, a hair growth and hair growth effect and a treatment and prevention effect of hair loss can be expected.
Detailed description of the invention
In the present invention, “hair growth” and “hair growth” mean not only hair growth and hair growth of scalp hair, but also hair growth and hair growth of body hair other than head hair, and prevention of shedding of head hair and body hair other than head hair. Including. In the present invention, “hair growth” is used to mean “hair growth”.
In the present invention, as a plant belonging to the genus Tisanoki, which is used as an active ingredient, there are fukumangi (Ehreia  microphylla,Carmona  retusa), Ryukyu Shanoki (Ehreia  dich otoma), Chishanoki (Ehreia  ovalifolia), Hiro bee chanoki (Ehreia  ovalifolia  var.  latifolia), Birch tree (Ehreia  dicksonii),Ehreia  acuminata,Ehreia  amoena,Ehreia  anacua,Ehreia  aspera,Ehreia  buxifolia,Ehreia  cymosa,Ehreia  grahamii,Ehreia  laevis,Ehreia  philippinensis,Ehreia  wallichianaIs mentioned. In the present invention, these plants can be used alone or in combination as an active ingredient.
Although any part of the plant used in the present invention may be used as an active ingredient, for example, leaves and stems can be used. The plant used in the present invention can be in the form of a dried product, a dried powder, an extract, and the like, and the extract is particularly preferable.
In the present invention, the term "extract" refers to an extract obtained by extracting a plant with a solvent, a diluent, a concentrate, and an extract thereof, and a dried product obtained by drying these by freeze-drying or the like. .
The plant extract can be produced according to a known method. That is, after a plant, for example, a leaf, a dried leaf, a stem, or a dried stem is crushed, crushed, or cut, a polar or non-polar solvent is added thereto, and the mixture is extracted with an appropriate solvent. The extract can be obtained by removing insolubles by operations such as filtration and centrifugation according to the concentration, and concentrating the extract. If necessary, the product may be purified by washing with water and extracting with a non-polar solvent such as ethyl acetate, diethyl ether, and hexane.
Examples of the "solvent" used for the extraction include water; alcohols such as methanol, ethanol, 1-propanol, 2-propanol and 1-butanol; ethers such as 1,4-dioxane; ketones such as acetone; Examples include polar solvents such as nitriles. The "solvent" used for the extraction includes aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as tetrahydrofuran, dioxane and monoglyme; halogens such as methylene chloride, chloroform and carbon tetrachloride. Hydrocarbon; ethyl acetate; or a mixture thereof. Preferred solvents are water; lower alcohols such as methanol and ethanol; and mixtures thereof.
Dry plant powder can be produced according to a known method. For example, a dried powder can be obtained by drying a plant to obtain a dried product, and then cutting and / or pulverizing the dried product. Examples of the method for drying the plant include methods such as heat drying, drying under reduced pressure, and air drying. As a method for cutting and crushing plants, for example, after cutting or crushing dried plants (for example, leaves and stems) into small pieces or lumps, or after rough cutting, middle cutting, or fine cutting, a crusher, etc. And pulverizing the powder into coarse powder, medium powder, fine powder, or fine powder.
The microfilon derivative can be isolated by applying the extract of Fukumangi to a suitable known separation means, for example, a silica gel chromatography method, a high performance liquid chromatography method, or the like.
The microfilon derivative can be represented by the following formula (I).
Figure 2003022231
(In the above formula, R1Represents a hydrogen atom or an alkyl group;2Is a hydrogen atom, a vinyl group which may have a substituent or an allyl group which may have a substituent (-CH2-CH = CH2) And R3Represents a hydrogen atom; R2And R3May together form a bond or an alkylene chain having 1 to 5 carbon atoms which may have a substituent, A represents an oxygen atom, a sulfur atom or a single bond;−−−Represents a single bond or a double bond)
In the formula (I), R1Examples of the alkyl group which may be represented by a linear or branched alkyl group having 1 to 8 carbon atoms, preferably a linear or branched alkyl group having 1 to 5 carbon atoms, such as methyl, ethyl and n -Propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl are particularly preferred.
R2As a substituent of the vinyl group which may be represented by, an alkyl group having 1 to 5 carbon atoms which may have a substituent such as a hydroxy group or an alkoxy group having 1 to 5 carbon atoms (for example, -C (- CH3)2(-CHOH)); an alkenyl group having 2 to 5 carbon atoms which may have a substituent such as a hydroxy group or an alkoxy group having 1 to 5 carbon atoms (for example, -C (-CH3) (= CH2)); An alkoxy group having 1 to 5 carbon atoms which may have a substituent such as a hydroxy group or an alkoxy group having 1 to 5 carbon atoms; a hydroxy group; a carboxyl group; an amino group.
R2Examples of the substituent of the allyl group which may be represented by a hydroxy group, an alkyl group having 1 to 5 carbon atoms which may have a substituent such as an alkoxy group having 1 to 5 carbon atoms (for example, 1 or 2 A methyl group); an optionally substituted alkenyl group having 2 to 5 carbon atoms such as a hydroxy group or an alkoxy group having 1 to 5 carbon atoms; a substituent such as an alkoxy group having 1 to 5 carbon atoms or the like; A hydroxy group; a carboxyl group; an amino group and the like.
R2And R3May together form a bond or an alkylene chain having 1 to 5 carbon atoms, preferably 1 to 3 carbon atoms. In this case, the ring that can be formed includes a cycloalkane having 3 to 8 carbon atoms, preferably a cycloalkane having 3 to 6 carbon atoms (eg, cyclopropane, cyclobutane, cyclopentane). The alkylene chain may have a substituent in some cases. Examples of such a substituent include a hydroxy group and a carbon atom having 1 to 5 carbon atoms which may have a substituent such as an alkoxy group having 1 to 5 carbon atoms. Alkyl group having 5 to 5 carbon atoms; an alkenyl group having 2 to 5 carbon atoms which may have a substituent such as a hydroxy group and an alkoxy group having 1 to 5 carbon atoms (for example, -C (-CH3) (= CH2)); An alkoxy group having 1 to 5 carbon atoms which may have a substituent such as a hydroxy group or an alkoxy group having 1 to 5 carbon atoms; a hydroxy group; a carboxyl group; an amino group.
Preferred compounds of formula (I) include R1Represents an alkyl group having 1 to 8 carbon atoms;2Represents a vinyl group which may have a substituent or an allyl group which may have a substituent;3Represents a hydrogen atom, A represents a single bond,−−−Represents a double bond, and more preferably R1Represents an alkyl group having 1 to 5 carbon atoms;2Represents an allyl group which may have a substituent;3Represents a hydrogen atom, A represents a single bond,−−−Is a compound representing a double bond, and particularly preferably R1Represents methyl, and R2Is allyl substituted by two methyls (-CH2-CH = C (-CH3)2) And R3Represents a hydrogen atom, A represents a single bond,−−−Is a compound representing a double bond.
The compound of formula (I) may have various isomers such as geometric isomers such as cis- and trans-forms, optical isomers such as d-form and l-form, and rotamers. All of these isomers are included.
The composition according to the present invention contains, if necessary, a plant extract such as carrot extract, assembly extract, garlic extract, aloe extract, and pepper extract; vitamins B6, vitamin E and its derivatives, vitamins such as biotin; glycyrrhizic acid; An anti-inflammatory agent such as glycyrrhetinic acid and diphenhydramine hydrochloride; a bactericide such as hinokitiol, phenoxyethanol and salicylic acid; an anti-androgen such as estradiol; a mineral such as zinc; and a synthetic drug such as minoxidil can be further added. In addition, as long as the effects of the present invention are not impaired, a surfactant, an antioxidant, a fragrance, a gelling agent, a coloring agent, a preservative, a keratolytic agent, a pH adjuster, an alcohol, water and the like according to the present invention. It can be appropriately compounded in a product.
The composition according to the present invention can be used as a drug for the purpose of hair growth or hair growth, quasi-drugs, cosmetics, or food or drink. The administration form is not particularly limited, and examples thereof include general administration routes such as dermal administration, oral administration, and administration by injection.
Examples of preparations for dermal administration include various ointment, cream, gel, emulsion, liquid, lotion, shampoo, rinse, tonic, and aerosol-applicable various dosage forms, and solid preparations for oral administration. Examples include capsules, tablets, pills, troches, powders, granules, and the like.Liquid preparations for oral administration include inert diluents commonly used by traders at the time, such as water. And pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. These various preparations can be produced by conventional methods using preparation additives such as commonly used excipients, auxiliaries and additives.
When used as food, solid food, creamy, or jam-like semi-liquid food, gel food, it can be in any food form such as beverages, for example, powder, capsules, granules, Tablets, drinks and the like can be mentioned. These various foods may be manufactured using commonly used food additives.
The dose of the genus Vulgaris (e.g., Fukumangi) can be determined depending on the route of administration, the desired duration of treatment and other factors, but is generally about 5 to 1500 mg / kg per day, especially about 30 to 600 mg / kg. kg is preferred. If desired, the daily dose may be divided and administered in 2 to 4 times.
The effective dose of the fukumangi extract can be determined depending on the route of administration, the desired duration of treatment and other factors, but is generally about 5 to 750 mg / kg, preferably about 50 to 400 mg / kg per day. If desired, the daily dose may be divided and administered in 2 to 4 times.
The effective dose of the microphylon derivative can be determined depending on the route of administration, the desired duration of treatment and other factors, but is generally about 0.1 to 250 mg / kg per day, especially about 1 to 100 mg / kg. If desired, the daily dose can be divided and administered in 2 to 4 times.
The composition for hair growth and hair growth according to the present invention may be used for androgenetic alopecia, seborrheic alopecia, senile alopecia, alopecia areata, pityriasis alopecia, hair loss alopecia, drug alopecia, radiation By applying to alopecia such as alopecia and stress alopecia, hair growth and hair growth can be promoted and hair loss can be improved. That is, the composition according to the present invention can be used for treating and preventing these diseases.
Further, the composition for hair growth and hair growth according to the present invention has an effect of improving or preventing dandruff, kayumi, thin hair, hair loss and the like.
The composition for hair growth and hair growth according to the present invention can be used for animals other than humans, for example, mammals such as monkeys, dogs, cats, rabbits and guinea pigs, and birds such as parrots, parakeets and canaries. These animals are bred as pets, and many symptoms such as hair loss and hair loss due to stress or disease have been observed. Therefore, the composition for hair growth and hair growth according to the present invention is also effective for these animals.
According to the present invention, there is provided the use of a plant belonging to the genus Vulgaris, for the production of a hair growth or growth agent.
According to the present invention, there is also provided the use of a microfilon derivative for producing a hair growth or growth agent.
According to the present invention, there is provided a method for hair growth or hair growth comprising the step of administering a therapeutically or prophylactically effective amount of a plant belonging to the genus Titanaceae to a mammal together with a pharmaceutically acceptable carrier if necessary. You.
According to the present invention, there is also provided a method for hair growth or hair growth, comprising the step of administering to a mammal a therapeutically or prophylactically effective amount of a microfilon derivative together with a pharmaceutically acceptable carrier if necessary. .
According to a preferred embodiment of the present invention, there is provided a hair-growing or hair-restoring composition comprising an extract of Fukumangi as an active ingredient.
According to a preferred embodiment of the present invention, there is provided the use of an extract of Fukumangi for the production of a hair growth or growth agent.
According to a preferred embodiment of the present invention, there is provided a method for hair growth or hair growth comprising the step of administering to a mammal a therapeutically or prophylactically effective amount of an extract of Fukumangi together with a pharmaceutically acceptable carrier if necessary. Provided.
Example
Hereinafter, the present invention will be described in detail with reference to Examples, but the present invention is not limited thereto.
Example 1: Preparation of methanol extract of fukumangi and bulk powder of microfilon (1)
4 kg of fukumangi leaves were heated and extracted with 3 liters of methanol. After filtration, 3 l of methanol was added to the residue, and extraction was performed in the same manner. This extraction operation was performed four times in total. The filtrates were combined and the solvent was distilled off to obtain 450 g of a methanol extract. This methanol extract was dissolved in 70% (v / v) methanol, extracted with ether, and the solvent was distilled off to obtain 200 g of an ether extract. This ether extract was fractionated by silica gel column chromatography (solvent, hexane: ethanol = 5: 1) to obtain 10 g of a microfilon-containing fraction. This fraction was further fractionated by RP-18 column chromatography (solvent, 65% methanol), and the crude microfilon obtained was recrystallized with ethanol to obtain 150 mg of microfilone bulk powder.
Example 2: Preparation of Fukumangi ethanol extract and microfilon bulk powder (2)
1 kg of Fukumangi stem was subjected to warm extraction with 3 L of ethanol. After filtration, 3 l of ethanol was added to the residue, and extraction was performed in the same manner. This extraction operation was performed four times in total. The filtrates were combined and the solvent was distilled off to obtain 80 g of an ethanol extract. This ethanol extract was fractionated by silica gel column chromatography (solvent, hexane: ethanol = 5: 1) to obtain 8 g of a microfilon-containing fraction. This fraction was further fractionated by RP-18 column chromatography (solvent, 65% methanol), and the crude microfilon obtained was recrystallized with ethanol to obtain 500 mg of microfilone bulk powder.
Example 3: Preparation of microfilon ointment
2.5 mg of the microfilon bulk powder (Example 1) was placed on a pottery ointment kneading dish, and after dropping one drop of liquid paraffin, it was mixed and dissolved using a glass rod. While mixing with a spatula, 0.25 g of ointment base plastibase was added little by little and kneaded to prepare 1% microfilon ointment. The prepared microfilon ointment was stored in a cool place.
Example 4: Preparation of Fukumangi extract ointment
10 mg of fukumangi ethanol extract (Example 2) was placed on a pottery ointment kneading dish, and several drops of liquid paraffin were added thereto, followed by mixing and dissolving using a glass rod. While mixing with a spatula, 0.2 g of an ointment base plastibase was added little by little and kneaded to prepare a 5% fukumangi extract ointment. The prepared 5% fukumangi extract ointment was stored in a cool place.
Example 5 Hair growth and hair growth effect test of 1% microfilon ointment (hair growth and hair growth effect by application to trunk shaved area)
After shaving the body hair of the trunk from the abdomen to the back of the BDF1 mouse with a hair clipper, about 200 mg of 1% microphyllone ointment (Example 3) was thinly applied to the shaved part (applied area: about 25 cm)2). Seven days later, about 200 mg of microfilon ointment was applied again, and hair growth and hair growth were observed 16 days and 24 days after the start of the experiment. As a control group, a plastibase ointment containing no microfilon was applied in the same manner, and the state of hair growth and hair growth was observed. The observation results are shown in FIGS. 1a and 1b. In the 1% microphyllone ointment-applied group, hair growth and hair growth were vigorous at the shaved portion of the trunk from the abdomen to the back, and marked hair growth and hair growth effects were observed as compared with the plastibase control group.
Example 6: Hair growth and hair growth effects on whiskers
The body hair of the trunk from the abdomen to the back was shaved off with a hair clipper, the whiskers of the BDF1 mouse were cut off with scissors, and about 200 mg of 1% microphyllone ointment (Example 3) was thinly applied to the shaved portion (applied area of approx. 25cm2). Seven days later, about 200 mg of microfilon ointment was applied again, and the elongation of the whisker was observed 24 days after the start of the experiment. As a control group, BDF1 mice similarly coated with plastibase ointment containing no microfilon were used. As shown in FIG. 2, remarkable elongation of the whiskers was observed in the microfilon ointment-applied group compared to the control group. This result indicates that microfilon is transdermally absorbed and exhibits hair growth and hair growth effects in areas other than those directly applied.
Example 7: Muzzle hair growth and hair growth effect by application to auricle
Balb / c mice were cut off their whiskers with scissors, and then about 40 mg of 1% microphyllone ointment (Example 3) was applied to the front and back of the left and right auricles, and 15 days after the start of the experiment, whiskers and hair growth were observed. did. As a control group, a plastibase ointment containing no microfilon was used. When the microfilon ointment was applied to the auricle, remarkable stretching of the whiskers was observed as compared to the control group as shown in FIG. At the same time, hair growth and hair growth effects of trunk body hair were also observed, and when taken together with the results shown in Example 6, microfilon was transdermally absorbed to express its hair growth and hair growth effects, and not only body hair but also cheeks It shows that it has hair growth and hair growth effects on beards as well.
Example 8: Hair growth and hair growth effect test of 5% fukumangi ethanol extract ointment (hair growth and hair growth effect by application to trunk shaved area)
After shaving the body hair of the trunk from the abdomen to the back of the BDF1 mouse with a hair clipper, about 200 mg of 5% fukumangi extract ointment (Example 4) was thinly applied to the shaved part (applied area: about 25 cm)2). Seven days later, about 200 mg of microfilon ointment was applied, and two weeks later, the state of hair growth and hair growth was observed. As a control group, a plastibase ointment containing no fukumangi extract was applied in the same manner, and the state of hair growth and hair growth was observed. FIG. 4 shows the observation results. In the 5% fukumangi extract ointment group, hair growth and hair growth were more active in the shaved portion of the trunk from the abdomen to the back than in the plastic base control group, and remarkable hair growth and hair growth effects were observed. Furthermore, the elongation of the whiskers significantly accelerated in the fukumangi extract-applied group as compared to the control group (FIG. 5).
Example 9: Hair growth and hair growth effects by intravenous administration of microphylon
After shaving the body hair of the trunk from the abdomen to the back of the BDF1 mouse with a hair clipper, microfilon bulk powder (Example 1) dissolved in physiological saline was administered at a dose of 2 mg / kg and 6 mg / kg via the tail vein. . As a control, physiological saline was similarly intravenously administered. When hair growth and hair growth were observed 2 weeks after administration, significant hair growth and hair growth effects were observed in the microphylon-administered group as in the case of application to the trunk at any dose. The hair growth effect was dose-dependent. Therefore, microphylon and fukumangi extract have hair growth and hair growth effects not only by external use but also by administration such as intravenous administration and oral administration.
Example 10: Preparation of microfilon lotion
120 mg of bulk microfilon powder (Example 1) was placed in a container, and 3.2 ml of ethanol and 0.8 ml of propylene glycol were added and dissolved. Microfilon lotion was prepared fresh before use.
Example 11: Preparation of Fukumangi Extraction
200 mg of fukumangi ethanol extract (Example 2) was placed in a container, and 3.2 ml of ethanol and 0.8 ml of propylene glycol were added thereto, followed by sonication for dissolution. The Fukumangi ethanol extraction lotion was prepared at the time of use.
Example 12: Hair growth effect test of 3% microfilon lotion (hair growth effect by application to trunk shaved portion (back))
After shaving the back hair of the C3H mouse with a hair clipper, 200 μl of 3% microfilon lotion (Example 10) was applied to the shaved portion once a day successively from the next day (applied area: about 20 cm)2). To examine the hair growth status 31 days after the start of the experiment, the skin at the shaved portion was peeled off, and the area ratio of the hair growth portion was calculated by the following formula. As a control group, a lotion containing no microfilon was applied in the same manner, and the regenerated area ratio of the hair growth part 31 days after the start of the experiment was calculated in the same manner. Table 1 shows the results of the hair regeneration area ratio. In the 3% microfilon lotion application group, hair growth at the back shaved site was active, and a significant hair growth effect was observed as compared with the lotion control group.
Figure 2003022231
Example 13: Hair growth effect test of 5% fukumangi ethanol extract (hair growth effect by application to trunk shaved area (back))
After shaving the back hair of the C3H mouse with a razor, 200 μl of 5% Fukumangi Extract (Example 11) was applied to the shaved portion once a day successively from the next day (applied area: about 20 cm).2). 15 days after the start of the experiment, the skin in the shaved area was peeled off and the area ratio of the hair-grown area was calculated by the following formula in order to check the hair growth situation. As a control group, a lotion containing no fukumangi extract was applied in the same manner, and the regenerated area ratio of the hair growth portion 15 days after the start of the experiment was similarly calculated. Table 2 shows the results of the hair regeneration area ratio. In the group to which the 5% fukumangi extract was applied, hair growth at the back shaved site was active, and a significant hair growth effect was observed as compared with the lotion control group.
Figure 2003022231

[Brief description of the drawings]
FIG. 1 is a photograph of a biological morphology showing the hair growth and hair growth effects when a plastibase ointment (Vehicle) and 1% microphyllone ointment (1% microphyllon) containing no microfilon were applied to the trunk shaving portion of a BDF1 mouse. It is. a is the result on the 16th day and b is the result on the 24th day.
FIG. 2 is a photograph of the form of an organism showing the effect of promoting the growth of whiskers when a plastibase ointment containing no microfilon (Vehicle) and a 1% microfilon ointment (Microphyllon) are applied to the trunk shaving portion of a BDF1 mouse. .
FIG. 3 shows the effect of promoting whisker elongation when a plastibase ointment (Vehicle (ear)) and 1% microphylone ointment (MP (ear)) containing no microfilon were applied to the auricle of a Balb / c mouse. It is a photograph of the form of the representing organism.
FIG. 4 shows the forms of organisms showing the hair growth and hair growth effects when plastibase ointment containing no fukumangi extract (control group) and 5% fukumangi extract ointment (fukumangi group) were applied to the shaved trunk of BDF1 mice. It is a photograph of.
Fig. 5 shows the effect of promoting the growth of cheek whiskers when a plastibase ointment containing no fukumangi extract (control group) and a 5% fukumangi extract ointment (fukumangi group) were applied to the shaved trunk of BDF1 mice. It is a photograph of a form.

Claims (18)

ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物を有効成分として含んでなる、発毛用または育毛用組成物。A hair-growing or hair-restoring composition comprising, as an active ingredient, a boraginaceae ( Boraginaceae ) plant of the genus Ehretia . ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物がフクマンギ(Ehretia microphyllaCarmona retusa)である、請求項1に記載の組成物。Boraginaceae (Boraginaceae) ehretia acuminata genus (Ehretia) plants Fukumangi (Ehretia microphylla, Carmona retusa) is a composition of claim 1. 植物の抽出物または乾燥粉末を有効成分として含んでなる、請求項1または2に記載の組成物。The composition according to claim 1 or 2, comprising a plant extract or a dry powder as an active ingredient. ミクロフィロン誘導体を有効成分として含んでなる、発毛用または育毛用組成物。A hair-growing or hair-growing composition comprising a microfilon derivative as an active ingredient. ミクロフィロン誘導体が式(I)で表わされる、請求項4に記載の組成物。
Figure 2003022231
(上記式中、Rは水素原子またはアルキル基を示し、Rは水素原子、置換基を有していてもよいビニル基または置換基を有していてもよいアリル基を示し、Rは水素原子を表し、RとRは一緒になって結合または置換基を有していてもよい炭素数1〜5のアルキレン鎖を形成してもよく、Aは酸素原子、硫黄原子または単結合を示し、−−−は単結合または二重結合を表す)
The composition according to claim 4, wherein the microphyllone derivative is represented by the formula (I).
Figure 2003022231
(In the above formula, R 1 represents a hydrogen atom or an alkyl group, R 2 represents a hydrogen atom, a vinyl group which may have a substituent, or an allyl group which may have a substituent, and R 3 Represents a hydrogen atom, R 2 and R 3 may together form a C 1-5 alkylene chain which may have a bond or a substituent, and A is an oxygen atom, a sulfur atom or Represents a single bond, and --- represents a single bond or a double bond)
男性型脱毛症、脂漏性脱毛症、老人性脱毛症、円形脱毛症、粃糠性脱毛症、結髪性脱毛症、薬物性脱毛症、放射線脱毛症、およびストレス性脱毛症からなる群から選択される疾患の治療または予防に用いられる、請求項1〜5のいずれか一項に記載の組成物。Select from the group consisting of androgenetic alopecia, seborrheic alopecia, senile alopecia, alopecia areata, pityriasis alopecia, alopecia areata, drug alopecia, radiation alopecia, and stress alopecia The composition according to any one of claims 1 to 5, which is used for treating or preventing a disease that is caused. 発毛剤または育毛剤の製造のための、ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物の使用。Use of a plant of the genus Boraginaceae ( Ehretia ) for the manufacture of a hair restorer or a hair restorer. ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物がフクマンギ(Ehretia microphyllaCarmona retusa)である、請求項7に記載の使用。The use according to claim 7, wherein the Boraginaceae plant is of the genus Ehretia ( Ehretia microphylla , Carmona retusa ). 植物が抽出物または乾燥粉末である、請求項7または8に記載の使用。Use according to claim 7 or 8, wherein the plant is an extract or a dry powder. 発毛剤または育毛剤の製造のための、ミクロフィロン誘導体の使用。Use of a microfilon derivative for the production of a hair growth or growth agent. ミクロフィロン誘導体が式(I)で表わされる、請求項10に記載の使用。
Figure 2003022231
(上記式中、Rは水素原子またはアルキル基を示し、Rは水素原子、置換基を有していてもよいビニル基または置換基を有していてもよいアリル基を示し、Rは水素原子を表し、RとRは一緒になって結合または置換基を有していてもよい炭素数1〜5のアルキレン鎖を形成してもよく、Aは酸素原子、硫黄原子または単結合を示し、−−−は単結合または二重結合を表す)
The use according to claim 10, wherein the microphyllone derivative is represented by formula (I).
Figure 2003022231
(In the above formula, R 1 represents a hydrogen atom or an alkyl group, R 2 represents a hydrogen atom, a vinyl group which may have a substituent, or an allyl group which may have a substituent, and R 3 Represents a hydrogen atom, R 2 and R 3 may together form a C 1-5 alkylene chain which may have a bond or a substituent, and A is an oxygen atom, a sulfur atom or Represents a single bond, and --- represents a single bond or a double bond)
発毛剤または育毛剤が男性型脱毛症、脂漏性脱毛症、老人性脱毛症、円形脱毛症、粃糠性脱毛症、結髪性脱毛症、薬物性脱毛症、放射線脱毛症、およびストレス性脱毛症からなる群から選択される疾患の治療または予防に用いられる、請求項7〜11のいずれか一項に記載の使用。Hair loss or hair restorer is male pattern baldness, seborrheic alopecia, senile alopecia, alopecia areata, pityriasis alopecia, hair loss alopecia, drug alopecia, radiation alopecia, and stress The use according to any one of claims 7 to 11, which is used for treating or preventing a disease selected from the group consisting of alopecia. ムラサキ科(Boraginaceae)チシャノキ属(Ehr etia)植物の有効量を哺乳類に投与する工程を含んでなる、発毛または育毛方法。Boraginaceae (Boraginaceae) ehretia acuminata genus (Ehr ETIA) an effective amount of a plant comprising the step of administering to a mammal, hair or hair growth method. ムラサキ科(Boraginaceae)チシャノキ属(Ehretia)植物がフクマンギ(Ehretia microphyllaCarmona retusa)である、請求項13に記載の方法。Boraginaceae (Boraginaceae) ehretia acuminata genus (Ehretia) plants Fukumangi (Ehretia microphylla, Carmona retusa) is a method according to claim 13. 植物の抽出物または乾燥粉末が投与される、請求項13または14に記載の方法。15. A method according to claim 13 or claim 14, wherein a plant extract or a dry powder is administered. ミクロフィロン誘導体の有効量を哺乳類に投与する工程を含んでなる、発毛または育毛方法。A hair growth or hair growth method comprising the step of administering an effective amount of a microphylon derivative to a mammal. ミクロフィロン誘導体が式(I)で表わされる、請求項16に記載の方法。
Figure 2003022231
(上記式中、Rは水素原子またはアルキル基を示し、Rは水素原子、置換基を有していてもよいビニル基または置換基を有していてもよいアリル基を示し、Rは水素原子を表し、RとRは一緒になって結合または置換基を有していてもよい炭素数1〜5のアルキレン鎖を形成してもよく、Aは酸素原子、硫黄原子または単結合を示し、−−−は単結合または二重結合を表す)
17. The method according to claim 16, wherein the microphylon derivative is represented by formula (I).
Figure 2003022231
(In the above formula, R 1 represents a hydrogen atom or an alkyl group, R 2 represents a hydrogen atom, a vinyl group which may have a substituent, or an allyl group which may have a substituent, and R 3 Represents a hydrogen atom, R 2 and R 3 may together form a C 1-5 alkylene chain which may have a bond or a substituent, and A is an oxygen atom, a sulfur atom or Represents a single bond, and --- represents a single bond or a double bond)
男性型脱毛症、脂漏性脱毛症、老人性脱毛症、円形脱毛症、粃糠性脱毛症、結髪性脱毛症、薬物性脱毛症、放射線脱毛症、およびストレス性脱毛症からなる群から選択される疾患が治療または予防される、請求項13〜17のいずれか一項に記載の方法。Select from the group consisting of androgenetic alopecia, seborrheic alopecia, senile alopecia, alopecia areata, pityriasis alopecia, alopecia areata, drug alopecia, radiation alopecia, and stress alopecia 18. The method according to any one of claims 13 to 17, wherein the disease to be treated is treated or prevented.
JP2003526361A 2001-09-10 2002-09-10 Hair growth and hair growth compositions Pending JPWO2003022231A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001273604 2001-09-10
JP2001273604 2001-09-10
PCT/JP2002/009192 WO2003022231A1 (en) 2001-09-10 2002-09-10 Compositions for stimulating and promoting hair growth

Publications (1)

Publication Number Publication Date
JPWO2003022231A1 true JPWO2003022231A1 (en) 2004-12-24

Family

ID=19098797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526361A Pending JPWO2003022231A1 (en) 2001-09-10 2002-09-10 Hair growth and hair growth compositions

Country Status (2)

Country Link
JP (1) JPWO2003022231A1 (en)
WO (1) WO2003022231A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5947061B2 (en) * 2012-02-29 2016-07-06 花王株式会社 SREBP1 inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08208499A (en) * 1995-02-07 1996-08-13 Sunstar Inc Composition for external use
JP3091962B2 (en) * 1998-09-25 2000-09-25 アルプス薬品工業株式会社 Testosterone-5α-reductase inhibitor
JP2000344632A (en) * 1999-06-07 2000-12-12 Ichimaru Pharcos Co Ltd Hair grower containing plant extract

Also Published As

Publication number Publication date
WO2003022231A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
CA2606392A1 (en) Hair tonic
JP3080767B2 (en) Hair restoration
JP2003137742A (en) Hair growing agent comprising evolvulus plant extract and other galenical extract
JP5059598B2 (en) Hair growth promoting composition
JP2002316917A (en) Hair tonic/hair growing agent, gray hair improving cosmetic
JPWO2003022231A1 (en) Hair growth and hair growth compositions
WO2005046630A1 (en) Hair restorer compositions and antipruritic agent
JPH04164013A (en) Skin, scalp and head hair-treating agent containing ingredient capable of preventing growth of pityrosporum ovale
JPH05286834A (en) Hair-raising agent
JP3382148B2 (en) External preparation for head
JPH06135821A (en) Hair tonic
JP3309914B2 (en) Hair restoration
JP6002510B2 (en) Estrogen receptor β activator
JP4577596B2 (en) Hair restorer or hair growth agent and method of use thereof
JP3309915B2 (en) Hair restoration
JP3014211B2 (en) Hair restoration
KR101177500B1 (en) Hair growth stimulating composition
JP3337845B2 (en) Hair restoration composition
JP3309916B2 (en) Hair restoration
JP7402478B2 (en) Nerve growth factor expression inhibitor and semaphorin 3A expression promoter
JP2008094784A (en) Hair growing or restoring agent
KR100651023B1 (en) Composition for improving hair growth comprising an non-polar solvent-soluble extract of Cantharis as an active ingredient
JP3020727B2 (en) Hair restoration
KR0173407B1 (en) Enhancing hair compositions containing alcohol abstracts of codonopsis pilosulate radix
JP2003012470A (en) Hair-growing cosmetic